Scientists develop sensor to detect vitamin B12 deficiency


Vitamin B12

Related Articles

Vitamin B12 deficiency has been associated with an increased risk of dementia and Alzheimer's disease. So University of Adelaide researchers developed an optical sensor that can detect vitamin B12 in diluted human blood.

It's a first step toward a low-cost, portable, broad-scale vitamin B12 deficiency test. The sensor enables doctors to track vitamin B12 levels in high-risk patients and allow for early intervention should levels dip too low.

The research, by scientists in the ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), the Institute for Photonics and Advanced Sensing and the Schools of Physical Sciences and Medicine was presented this week at the inaugural SPIE BioPhotonics Australasia conference. Biophotonics is the science of using light, or optical technologies, to analyze and measure biological material.

"Vitamin B12 deficiency has been shown to be a potential modifiable risk factor for dementia and Alzheimer's disease and is associated with cognitive decline," says Dr. Georgios Tsiminis, Research Fellow at the University of Adelaide. "Older adults are particularly at risk of B12 deficiency due to age-related reduction in absorbing vitamin B12 received through their diet."

The sensor is still at proof-of-concept stage but, with development, has wide-reaching potential applications.

"Currently our device could not aid in diagnosing vitamin B12 deficiency in a general practice setting," says Dr Tsiminis. "However, this is the first time a rapid technique based on optical spectroscopy has been shown to be able to detect vitamin B12 in human blood serum. We believe this is a very promising first step toward achieving this goal."

The optical sensor measurement of B12 in human blood takes less than a minute and requires minimum preparation. It's the first demonstration of the vitamin being measured in human blood serum without the need for a full laboratory test.

The sensor uses an optical measuring technique called Raman spectroscopy, which produces a unique optical fingerprint of a target molecule, in this case B12.

"Our method provides a realistic basis for a system that is portable, cost-effective, and affords rapid results, along the lines of the pin-prick test for diabetes," says Dr. Tsiminis. "Time and cost limitations currently mean that regular and frequent B12 measurements are not being carried out. Having such a device could make this testing routine, potentially having a real impact on dementia and Alzheimer's disease."